TY - JOUR T1 - Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study JF - Anticancer Research JO - Anticancer Res SP - 6941 LP - 6950 VL - 35 IS - 12 AU - LUÍS MANSO AU - ANDRÉS GARCÍA PALOMO AU - RAMÓN PÉREZ CARRIÓN AU - JAVIER CASSINELLO AU - ISABEL GALLEGOS SANCHO AU - IGNACIO CHACÓN LÓPEZ-MUÑIZ AU - CLARA OLIER AU - ANTONIO FERNÁNDEZ-ARAMBURO AU - CRISTINA LLORCA AU - XAVIER GONZÁLEZ AU - ROSA LLORENTE AU - DOLORES TORREGROSA AU - IÑAKI ÁLVAREZ AU - ELENA GÁLVE AU - CORALIA BUENO AU - ISABEL GARAU AU - MARÍA JOSÉ GARCÍA AU - SANTIAGO GONZÁLEZ-SANTIAGO AU - ANA ISABEL BALLESTEROS AU - ESPERANZA BLANCO AU - ANTONIO GALÁN AU - SONIA GONZÁLEZ AU - ANTONIA PERELLÓ AU - HERNÁN CORTÉS-FUNES AU - CRISTINA GRÁVALOS Y1 - 2015/12/01 UR - http://ar.iiarjournals.org/content/35/12/6941.abstract N2 - Aim: To evaluate factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer (MBC) in clinical practice in Spain. Patients and Methods: All consecutive adult female patients with HER2-negative MBC who had received first-line bevacizumab plus chemotherapy for at least 3 months were enrolled in the present study. Results: A total of 292 evaluable patients were included; 25% had triple-negative breast cancer (TNBC) and 75% had hormone receptor-positive breast cancer (HRPBC). Nearly 40% of patients had ≥3 metastatic sites, mainly located in the bone (48%) and liver (40%). Bevacizumab was mostly combined with paclitaxel (67.1%). ER-positive tumors were only identified as an independent factor associated with the choice of treatment (odds ratio (OR): 0.538; p=0.02). The overall response rate (ORR) was 63.7% (TNBC: 57.5%; HRPBC: 65.9%). Patients aged 36-50 years (OR: 3.03; p=0.028) and those with metastases at sites other than the bone (OR: 0.38; p=0.001) and ≥3 metastatic sites (OR: 1.41; p=0.018) were more likely to achieve objective responses. Conclusion: First-line bevacizumab plus chemotherapy, mainly paclitaxel, is an effective and well-tolerated treatment option for HER2-negative MBC, particularly in more aggressive disease. ER -